Drug intelligence / Profile preview

nicotinamide-expanded natural killer cells

Development stage: Phase 1
Lead developer: Gamida Cell
Modality: CAR-NK Cells → Other Engineered Cells → Adoptive Cell Transfer → Cell Therapies, Lymphokine-Activated Killer Cells → Native Immune Cells → Adoptive Cell Transfer → Cell Therapies
Administration: Intravenous

Overview

Nicotinamide-expanded natural killer cells, also known as GDA-201 or NAM-NK cells, are allogeneic natural killer (NK) cells expanded ex vivo in the presence of nicotinamide (NAM) and interleukin-15 (IL-15). NAM enhances NK cell stability, survival, cytotoxic activity, glucose metabolism, resilience under oxidative stress, and cytokine production. These cells demonstrate potent cytolytic and antineoplastic activities and are being developed as cell therapies, particularly in combination with monoclonal antibodies such as rituximab or elotuzumab. Mechanistically, NAM-NK cells exhibit enhanced persistence after adoptive transfer, improved homing to lymph nodes via increased CD62L expression, and have been further engineered with CRISPR-Cas9 technology for CD38 knockout and chimeric antigen receptor (CAR) expression to improve targeting of multiple myeloma[1][2][3][4][7].

Brand names: GDA-201GDA201GDA 201
Other names: NAM-NK cellsallogeneic nicotinamide (NAM)-expanded natural killer cellsnicotinamide-supported NK cellsdonor nicotinamide-expanded natural killer cells

Targets

CD38 (Cluster of Differentiation 38)IL-15R (Interleukin 15 receptor alpha/interleukin 15 complex)

Beyond the preview

Go deeper on nicotinamide-expanded natural killer cells.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on nicotinamide-expanded natural killer cells.

Explore the full profile